LONDON, Oct. 21, 2021 (GLOBE NEWSWIRE) — Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “ Company” or “Small Pharma”), a neuropharmaceutical company focused on psychedelic-assisted therapies, is pleased to announce that following discussions with the U.K. Medicines and Healthcare products Regulatory Agency (the “MHRA”), Small Pharma has been granted an Innovation Passport Designation for SPL026…


Previous articleTryp Therapeutics Reports Clinical Hold on Proposed Phase 2a Study in Eating Disorders
Next articlePTSF82 – Wonderland Miami, with Patrick Moher of Microdose